Drug Target Review Podcast Drug Target Review

In this podcast episode, we will be discussing how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy, focusing on degenerative muscle diseases.

This conversation features Frank Gleeson, CEO and co-founder of Satellos, and Dr Michael Rudnicki, co-founder and Chief Discovery Officer at Satellos.

Bringing their expertise, we are thrilled to introduce Dr Matthew Nelson, Vice President, Genetics and Genomics, Deerfield Discovery and Development and CEO at Genscience and Dr Jake Rubens, President of Quotient Therapeutics and Origination Partner at Flagship Pioneering.

Key discussion points:

DNA has been called the code of life. How much of this code have we deciphered?

How is technology evolving to allow us to better understand the consequences of genetic changes (DNA mutations, epigenetics, etc.) and health and disease? What impact do we expect this to have in drug discovery?

How do we go from sequencing the DNA of individuals to making connections to health and disease? What are some examples of gene-disease links we’ve made that have informed drug target selection?

This podcast is in association with Molecular Devices. With its innovative life science technology, Molecular Devices makes scientific breakthroughs possible for academic, pharmaceutical, government and biotech customers. Head to moleculardevices.com to find out more.

In this podcast episode, titled ‘Investigating the promising future of organoids’, we will be discussing the ways in which organoids are being used to study diseases and improve drug development. We explore the specific preclinical models organoids are replacing, the current limitations of organoids and how to overcome these, as well as where the field is heading. 

This conversation features Dr Radhika Menon, Senior Scientist of Neurobiology at Ncardia, Dr Etienne De Braekeleer, Senior Research Scientist at AstraZeneca, and Dr Paige Vinson, Director of High Throughput Screening at Southern Research.

In this podcast episode titled 'Breaking resistance - the future of immunotherapy in oncology' we will be discussing checkpoint inhibitors in cancer therapy, and how primary and secondary treatment resistance are still limiting their clinical success in a variety of cancer types. In this episode, we want to explore the current status and potential solutions to addressing this major hurdle in oncology.

This conversation features Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, and Roy Baynes, Chief Scientific Officer at Eikon Therapeutics.

In this episode titled: CRISPR/Cas: exploring its impact on gene editing, we explore the latest technological advancements in the field and more.

This conversation features Dr Pietro De Angeli, Scientist at Tubingen University Hospital, and Dr Maarten Guerts, Postdoctoral Fellow at the Princess Maxima Center for Pediatric Oncology.

Key learning points: 

What comparative safety profiles exist between utilising plasmid DNA, mRNA, and ribonucleoproteins (RNPs) as delivery systems for CRISPR/Cas components in gene editing therapies?
In what ways might the use of different ex-vivo applications affect the scalability and feasibility of large-scale gene editing treatments?

How might the convergence of CRISPR/Cas technology with Artificial Intelligence/Machine Learning improve precision medicine?

In this episode titled: High throughput screening: rapid advancements in drug discovery, we explore the latest technological advancements in the field and more.

This conversation features Dr Luke Alderwick, Senior Group Leader in HTS/Hit ID at Early Discovery at Charles River Laboratories (CRL), and Dr Sachin Mahale, Research Leader in High Throughput Screening at Charles River Laboratories.